Company intelligence / Profile preview
Guangzhou Runer Ophthalmic Biotechnology
Guangzhou, Guangdong Sheng, Chinagz.gov.cn ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Guangzhou Runer Ophthalmic Biotechnology has a pipeline focused on small molecule drugs for ophthalmology and related indications, with at least four programs in clinical development. Two programs are in Phase 2, one is in Phase 3 or NDA/BLA stage. The company’s lead asset includes epinastine hydrochloride targeting the histamine H1 receptor for eye disease.
- Therapeutic areas
- PulmonologyImmunologyDermatologyOphthalmologyNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangzhou Runer Ophthalmic Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Runer Ophthalmic Biotechnology.